-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Synaptogenix (NASDAQ:SNPX) Stock Price Down 3.7%
Synaptogenix (NASDAQ:SNPX) Stock Price Down 3.7%
Synaptogenix, Inc. (NASDAQ:SNPX – Get Rating)'s share price was down 3.7% during trading on Tuesday . The stock traded as low as $7.85 and last traded at $7.99. Approximately 30,751 shares traded hands during trading, a decline of 67% from the average daily volume of 92,223 shares. The stock had previously closed at $8.30.
Synaptogenix Stock Down 3.7 %
The business has a 50-day simple moving average of $6.41 and a two-hundred day simple moving average of $6.34. The stock has a market capitalization of $54.66 million, a price-to-earnings ratio of -3.80 and a beta of 0.91.
Get Synaptogenix alerts:Synaptogenix (NASDAQ:SNPX – Get Rating) last issued its quarterly earnings results on Friday, August 5th. The company reported ($0.54) EPS for the quarter.
Institutional Trading of Synaptogenix
Several hedge funds have recently added to or reduced their stakes in SNPX. Prelude Capital Management LLC lifted its stake in Synaptogenix by 13.9% during the second quarter. Prelude Capital Management LLC now owns 14,364 shares of the company's stock worth $75,000 after purchasing an additional 1,750 shares during the period. Renaissance Technologies LLC bought a new position in shares of Synaptogenix during the 2nd quarter worth approximately $83,000. Finally, Vanguard Group Inc. grew its position in Synaptogenix by 248.9% in the first quarter. Vanguard Group Inc. now owns 216,836 shares of the company's stock valued at $1,678,000 after acquiring an additional 154,688 shares during the period. Institutional investors own 9.10% of the company's stock.About Synaptogenix
(Get Rating)
Synaptogenix, Inc operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. It focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer's disease. The company is also evaluating therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease.
Featured Articles
- Get a free copy of the StockNews.com research report on Synaptogenix (SNPX)
- 3 Low Beta Defensive Stocks for a Tough Market
- It Could Be a September to Remember for These 3 Stocks
- Peak Inflation Sets the Bottom for Brinker International Stock
- Can Roblox Reverse its Falling Bookings Amid Rising Engagements
- Broadcom Bounces From Institutional Bottom
Receive News & Ratings for Synaptogenix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synaptogenix and related companies with MarketBeat.com's FREE daily email newsletter.
Synaptogenix, Inc. (NASDAQ:SNPX – Get Rating)'s share price was down 3.7% during trading on Tuesday . The stock traded as low as $7.85 and last traded at $7.99. Approximately 30,751 shares traded hands during trading, a decline of 67% from the average daily volume of 92,223 shares. The stock had previously closed at $8.30.
新创科技股份有限公司(纳斯达克代码:SNPX-GET Rating)股价周二下跌3.7%,最低报7.85美元,尾盘报7.99美元。全天约有30,751股股票易手,较平均日成交量92,223股下跌67%。该股此前收盘报8.30美元。
Synaptogenix Stock Down 3.7 %
Synaptogenix股价下跌3.7%
The business has a 50-day simple moving average of $6.41 and a two-hundred day simple moving average of $6.34. The stock has a market capitalization of $54.66 million, a price-to-earnings ratio of -3.80 and a beta of 0.91.
该业务的50日简单移动均线切入位在6.41美元,200日简单移动均线切入位在6.34美元。该股市值为5,466万美元,市盈率为-3.8倍,贝塔系数为0.91。
Synaptogenix (NASDAQ:SNPX – Get Rating) last issued its quarterly earnings results on Friday, August 5th. The company reported ($0.54) EPS for the quarter.
Synaptogenix(纳斯达克代码:SNPX-GET Rating)上一次发布季度收益报告是在8月5日星期五。该公司公布了该季度每股收益(0.54美元)。
Institutional Trading of Synaptogenix
Synaptogenix的制度性交易
About Synaptogenix
关于Synaptogenix
(Get Rating)
(获取评级)
Synaptogenix, Inc operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. It focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer's disease. The company is also evaluating therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease.
Synaptogenix公司是一家生物制药公司,在临床前和临床开发方面有候选产品。它专注于开发一个基于一种名为Bryostatin-1的候选药物的产品平台,用于治疗阿尔茨海默病。该公司还在评估bryostatin在其他神经退行性或认知疾病和功能障碍方面的治疗应用,如脆性X综合征、多发性硬化症和Niemann-Pick C型疾病。
Featured Articles
专题文章
- Get a free copy of the StockNews.com research report on Synaptogenix (SNPX)
- 3 Low Beta Defensive Stocks for a Tough Market
- It Could Be a September to Remember for These 3 Stocks
- Peak Inflation Sets the Bottom for Brinker International Stock
- Can Roblox Reverse its Falling Bookings Amid Rising Engagements
- Broadcom Bounces From Institutional Bottom
- 免费获取StockNews.com关于Synaptogenix的研究报告(SNPX)
- 3低贝塔防御性股票为艰难的市场做准备
- 对于这三只股票来说,这可能是一个值得记住的9月
- 通胀峰值为布林克国际股票设定底部
- 在预订增加的情况下,Roblox能否扭转预订量下降的局面
- 博通从机构底部反弹
Receive News & Ratings for Synaptogenix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synaptogenix and related companies with MarketBeat.com's FREE daily email newsletter.
接受Synaptogenix Daily的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对Synaptogenix和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧